A congressional hearing will take place regarding quality control practices both at McNeil and parent company Johnson & Johnson, the Chicago Tribune indicates.
After the massive recall of Tylenol and other over-the-counter drugs, the Food and Drug Administration (FDA) inspected the quality control practices being implemented at a Pennsylvania plant run by McNeil Consumer Health Care, a subsidiary of pharmaceutical Johnson & Johnson. FDA declared there is an inadequate training for its employees. Its latest Tylenol recall of 40 products happened April 30 that could have stripped $400 million from the company.
Other defects include substandard equipment, bacterial contamination of materials, and around 46 neglected complaints even before the recall. Good manufacturing practice is missing, said Prabir Basu, Purdue University.
Professor of Pharmacoecomomics Albert Wertheimer at Temple University believes it contributed to the shrinkage in its workforce.”I would suspect it’s a matter of trying to get by with less, but in this case it didn’t work,” he scrutinized.
Other McNeil plants under investigation are based in Lancaster, Pa., and Las Piedras, Puerto Rico.
Related posts:
- Tylenol Recall 2010 by McNeil Consumer Healthcare
- McNeil Promises Quality Repair
- Congress Investigates Johnson & Johnson